Oncolytics Biotech (ONCY) Total Liabilities (2009 - 2026)

Oncolytics Biotech (ONCY) has reported Total Liabilities for 18 consecutive years, with $13.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 38.09% year-over-year to $13.8 million in Q2 2026; TTM through Jun 2026 was $13.8 million, a 38.09% increase from a year earlier, with the FY2025 full-year figure at $11.4 million, up 12.43% from the prior year.
• Total Liabilities was $13.8 million for Q2 2026 at Oncolytics Biotech, up from $11.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $13.8 million in Q2 2026 and troughed at $7.1 million in Q1 2023.
• A 5-year average of $9.5 million and a median of $9.2 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 57.23% in 2023 and declined 12.47% in 2024, its largest moves.
• Over 5 years, Total Liabilities stood at $8.0 million in 2022, then climbed by 3.62% to $8.3 million in 2023, then increased by 22.97% to $10.2 million in 2024, then increased by 11.93% to $11.4 million in 2025, then grew by 21.59% to $13.8 million in 2026.
• The last three Total Liabilities figures came in at $13.8 million (Q2 2026), $11.4 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.